An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors

Chinese Medical Journal

Volumn 126, Issue 9, 2013, Pages 1642-1646

  Chi, Yihebali ^a   Zhan, Xiao Kai ^b   Yu, Hao ^c   Xie, Guang Ru ^c   Wang, Zhen Zhong ^d   Xiao, Wei ^d   Wang, Yong Gang ^e   Xiong, Fu Xing ^f   Hu, Jun Feng ^g   Yang, Lin ^a   Cui, Cheng Xu ^a   Wang, Jin Wan ^a  

^a CANCER HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Department of Breast Cancer   (China)

^e JIANGSU KANION PHARMACEUTICAL CO   (China)

^f SHANDONG UNIVERSITY   (China)

^g ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Advanced malignant tumor; Efficacy; Gambogic acid; Toxicity

Indexed keywords

GAMBOGIC ACID; MITOMYCIN; NITROSOUREA;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER PAIN; CHILL; CLINICAL ARTICLE; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENERGY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INJECTION SITE REACTION; IRRITABILITY; LIVER CANCER; LUNG METASTASIS; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SWELLING; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NEOPLASMS; XANTHONES;

EID: 84876901209     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122582     Document Type: Article

References (23)

1. Jiangsu New Medical School. Encyclopedia of Chinese Materia Medica, Volume II. Shanghai: The Shanghai People's Press; 1977: 2695.
2. Lu GB, Yang XX, Huang QS Isolation of gambogic acid from gamboge and its structure. Acta Pharm Sin (Chin) 1984; 19: 636-639.
3. Chen BR. Anti-cancer component of gamboges, study I: isolation and structure identification of gambogic acid. Acta Acad Med Jiangxi 1980; 1.
4. Ye DH, Wu H. Comparison of gambogic acid content in gamboges and its processed products. China J Chin Mat Med (Chin) 1995; 20: 601-608.
5. Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, et al. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 2007; 28: 632-638.
6. Zhao Q, Yang Y, Yu J, You QD, Zeng S, Gu HY, et al. Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells. Cancer Lett 2008; 223-231.
7. Guo QL, You QD, Wu ZQ, Yuan ST, Zhao L. General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin 2004; 25: 769-774.
8. Zhao L, Guo QL, You QD, Wu ZQ, Gu HY. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull 2004; 27: 998-1003.
9. Guo QL, Qi Q, You QD, Gu H, Zhao L, Wu Z. Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol 2006; 99: 178-184.
10. Gu H, Wang X, Rao S, Wang J, Zhao J, Ren FL, et al. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53 expressing cancer cells. Mol Cancer Ther 2008; 7: 3298-3305.
11. Lu N, Yang Y, You QD, Ling Y, Gao Y, Gu HY, et al. Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Lett 2007; 258: 80-89.
12. Liu W, Guo QL, You QD, Zhao L, Gu HY, Yuan ST. Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J Gastroenterol 2005; 11: 3655-3659.
13. Pandey MK, Sung B, Ahn KS, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007; 110: 3517-3525.
14. Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci U S A 2005; 102: 12095-12100.
15. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 2008; 68: 1843-1850.
16. Wang J, Ma J, You Q, Zhao L, Wang F, Li C, et al. Studies on chemical modification and biology of a natural product, gambogic acid (II): Synthesis and bioevaluation of gambogellic acid and its derivatives from gambogic acid as antitumor agents. Eur J Med Chem 2010; 45: 4343-4353.
17. Wang X, Chen Y, Han QB, Chan CY, Wang H, Liu Z, et al. Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics 2009; 9: 242-253.
18. Tao Z, Zhou Y, Lu J, Duan W, Qin Y, He X, et al. Caspase-8 preferentially senses the apoptosis-inducing action of NG-18, a Gambogic acid derivative, in human leukemia HL-60 cells. Cancer Biol Ther 2007; 6: 691-696.
19. Zhao J, Qi Q, Yang Y, Gu HY, Lu N, Liu W, et al. Inhibition of alpha (4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid. Eur J Pharmacol 2008; 589: 127-131.
20. Zhou ZT, Wang JW. Phase I human tolerability trail of Gambogic acid. Chin New drugs (Chin) 2007; 16: 435-437.
21. Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L, et al. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther 2007; 6: 2429-2440.
22. Zhai D, Jin C, Shiau CW, Kitada S, Satterthwait AC, Reed JC. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2008; 7: 1639-1646.
23. Wang T, Wei J, Qian X, Ding Y, Yu L, Liu B. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett 2008; 262: 214-222.